Stephen J. Hill sold $29k of LYEL
Chief Operating Officer at Lyell Immunopharma, Inc.. 1,236 shares at an average of $23.39, traded Feb 11, 2026, filed Feb 12, 2026.
Score components
- +20RoleCOO
- +5Trade size$29k at market
- 0Share of holdings soldSold 6.5% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001866154-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 11, 2026 | SOpen-market sale Common Stock | -1,236 | $23.39 | $29k | 17,795 | Feb 12, 2026 |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LYELsell Lyell Immunopharma, Inc. | David Shook Chief Medical Officer | $6,350 500 shares | -2% | |
| 58Moderate | Lyell Immunopharma, Inc. | ARCH Venture Partners IX, LLC owner | $12M 488,090 shares | +52% | |
| 58Moderate | Lyell Immunopharma, Inc. | ARCH Venture Fund XIII, L.P. owner | $12M 488,090 shares | +52% | |
| 36Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $39k 1,671 shares | -9% | |
| 51Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $174k 7,455 shares | -9% | |
| 30Weak | Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $5,872 254 shares | -2% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $2,520 109 shares | -1% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $3,399 147 shares | -1% | |
| 40Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $10k 438 shares | -1% | |
| 28Weak | LYELsell Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $74k 2,072 shares | -22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.